KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Expenditures (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Capital Expenditures data on record, last reported at $149.4 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 61.34% year-over-year to $149.4 million; the TTM value through Dec 2025 reached $437.6 million, up 46.99%, while the annual FY2025 figure was $437.6 million, 46.99% up from the prior year.
  • Capital Expenditures reached $149.4 million in Q4 2025 per VRTX's latest filing, up from $101.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $149.4 million in Q4 2025 and bottomed at $33.6 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $68.8 million, with a median of $60.7 million recorded in 2021.
  • The widest YoY moves for Capital Expenditures: up 264.52% in 2021, down 70.02% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $61.8 million in 2021, then crashed by 45.63% to $33.6 million in 2022, then skyrocketed by 72.92% to $58.1 million in 2023, then surged by 59.38% to $92.6 million in 2024, then surged by 61.34% to $149.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $149.4 million in Q4 2025, $101.8 million in Q3 2025, and $145.7 million in Q2 2025.